Tower Research Capital (TRC)’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-14,743
| Closed | -$49K | – | 4433 |
|
|
2019
Q4 | $49K | Buy |
14,743
+9,318
| +172% | +$29.6K | ﹤0.01% | 1357 |
|
|
2019
Q3 | $17K | Sell |
5,425
-613
| -10% | -$1.72K | ﹤0.01% | 2597 |
|
|
2019
Q2 | $14K | Sell |
6,038
-7,953
| -57% | -$23.8K | ﹤0.01% | 2394 |
|
|
2019
Q1 | $53K | Buy |
13,991
+13,634
| +3,819% | +$51.1K | ﹤0.01% | 1745 |
|
|
2018
Q4 | $1K | Sell |
357
-486
| -58% | -$2.11K | ﹤0.01% | 3736 |
|
|
2018
Q3 | $5K | Sell |
843
-8,366
| -91% | -$47.9K | ﹤0.01% | 3158 |
|
|
2018
Q2 | $46K | Buy |
9,209
+8,425
| +1,075% | +$43.4K | ﹤0.01% | 1900 |
|
|
2018
Q1 | $4K | Buy |
+784
| New | +$4.72K | ﹤0.01% | 2825 |
|
|
2017
Q3 | – | Sell |
-4,872
| Closed | -$23K | – | 4322 |
|
|
2017
Q2 | $23K | Sell |
4,872
-1,346
| -22% | -$6.01K | ﹤0.01% | 1155 |
|
|
2017
Q1 | $31K | Buy |
6,218
+5,945
| +2,178% | +$57.2K | ﹤0.01% | 1014 |
|
|
2016
Q4 | $3K | Buy |
+273
| New | +$2.57K | ﹤0.01% | 3333 |
|
|
2016
Q3 | – | Sell |
-7,455
| Closed | -$47K | – | 4881 |
|
|
2016
Q2 | $47K | Buy |
7,455
+7,173
| +2,544% | +$47.6K | ﹤0.01% | 1601 |
|
|
2016
Q1 | $2K | Sell |
282
-1,076
| -79% | -$6.94K | ﹤0.01% | 3515 |
|
|
2015
Q4 | $11K | Sell |
1,358
-4,380
| -76% | -$32.7K | ﹤0.01% | 2054 |
|
|
2015
Q3 | $42K | Buy |
+5,738
| New | +$58.5K | ﹤0.01% | 1150 |
|
|
2014
Q4 | – | Sell |
-16,393
| Closed | -$89K | – | 5005 |
|
|
2014
Q3 | $89K | Buy |
+16,393
| New | +$94.1K | 0.01% | 1067 |
|
Tower Research Capital (TRC)'s FOMX Position: Q1 2020 in Review
Tower Research Capital (TRC) sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q1 2020, closing a stake of 14,743 shares — an estimated $49K sold.
Tower Research Capital (TRC) first reported a position in FOMX in Q3 2014 and held it in 16 quarters. The position peaked at $89K in Q3 2014. 3 funds tracked by Wall St. Rank hold FOMX as of Q1 2020.
- Tower Research Capital (TRC) reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q1 2020 after selling out during the quarter.
- Tower Research Capital (TRC) sold 14,743 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q1 2020, an estimated $49K.
- Tower Research Capital (TRC) first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q3 2014 and held it in 16 quarters.
- Tower Research Capital (TRC)'s Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $89K in Q3 2014.
- 3 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q1 2020.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2020, filed 15 May 2020.